Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Pharmacology Study of MR19A13A in Healthy Adult Males
jRCT2031230355Phase 1Completed
- Sponsor
- Maruishi Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of midazolam (2 arms), sponsored by Maruishi Pharmaceutical Co., Ltd. Primary endpoints: Plasma concentration and pharmacokinetic parameters of unchanged MR19A13A, Plasma concentration and pharmacokinetic parameters of 1-hydroxymidazolam and 5 more. Started Oct 2023; status: completed.
02
Drugs
midazolam
Beyond the preview
Go deeper on jRCT2031230355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230355.